Global Human Immunodeficiency Diseases (HIV) Rapid Test Kits Market Competitive Dynamics and Industry Outlook 2025
The global human immunodeficiency diseases (HIV) rapid test kits market was valued above USD 10 billion in 2019 and is anticipated to account for a CAGR over 5.0% over the forecast period. Human immune deficit Virus (HIV) is one of the most comprehensive and incurable diseases that cause HIV and AIDS. The number of HIV individuals worldwide has risen dramatically. In 2013, HIV is ranked 6th in the world among the world's deaths, with around 1.776.270 deaths in 2009, according to the World Health Organization (WHO). HIV is the second most common source of cancer death. More than 1,780,000 global death cases were filed in 2009, according to the same reports. On the other hand, in the last few years, an increase in the number of cases of infectious blood and infected needles was recorded.

Growing awareness of HIV and the number of attempts to bring an end to the disease propel the HIV rapid test kits market growth. Furthermore, the progress made in the diagnostic testing for HIV is expected to further increase the growth of the HIV (human immunodeficiency diseases). Several governments around the world are focusing on raising awareness regarding the development of modern HIV drugs. As a result, many initiatives like Let's stop HIV, Stop HIV, Start Talk and Stop HIV Stigma have been launched. As per World Health Organizations (WHO) 2015 database, globally around 37 million people were found to be HIV infected. Rising incidences of HIV infected people and the rapid demand for the treatment drugs and detection kits are the major factors driving the global market. Additionally, rising incidences of unprotected sex has increase prevalence of HIV/AIDS test kits, further leading to demand for curing drugs. Moreover, rising research and developments by the key players as well as investors to find the drugs for HIV infection and supportive government programs regarding HIV and AIDS will propel HIV test kits market in the near decade. However, ignorance regarding HIV infection in the developing and low-income economies such as China, India, Brazil are the major restrains for the global market. Moreover, companies are certain challenges in entering the market due to low rate of cautious screening for disease in African countries, which will impact the market growth in negative way. Some of the other factors such as increasing clinical studies, advertising efforts by vendors, and efforts to increase pre-marital screenings for HIV will spur the HIV rapid test kits market growth.

The global human immunodeficiency diseases (HIV) rapid test kits market is bifurcated on the basis of product, end-user and geography. The product segment includes HIV rapid molecular diagnostic test and HIV rapid immunoassay test. On the basis of end-user, the market is segmented into hospital, clinics and diagnostic centers. Based on region, the market is bifurcated into Asia-Pacific (APAC), Latin America, Europe, North America, and Middle East & Africa (MEA). Human Immunodeficiency Diseases (HIV) market has been further segmented into key countries.

Some of the key players operating in the market include F. Hoffmann-La Roche Ltd. Medtronic plc, Masimo Corporation, Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corp., And QIAGEN Group. Market players are involved in strategic acquisition and investment activities to maintain their market position over the existing players.

Chapter One: Market Introduction

Chapter Two: Executive Summary

Chapter Three: Global Human Immunodeficiency Diseases (HIV) market – Key Industry Dynamics
3.1. Key Market Drivers
3.2. Key Market Restraints
3.3. Market Opportunities
3.4. Future Trends
3.5. Impact Analysis of Drivers and Restraints

Chapter Four: Global Human Immunodeficiency Diseases (HIV) market – Analysis and Revenue Forecast, 2015-2025 – Product
4.1. HIV rapid immunoassay test
4.2. HIV rapid molecular diagnostic test

Chapter Five: Global Human Immunodeficiency Diseases (HIV) market – Analysis and Revenue Forecast, 2015-2025 – End-user
5.1. Hospital
5.2. Clinics
5.3. Diagnostic Centers

Chapter Six: Global Human Immunodeficiency Diseases (HIV) market – Analysis and Revenue Forecast, 2015-2025 – By Region
6.1. North America
6.2. Europe
6.3. Asia-Pacific
6.4. Latin America
6.5. Middle East & Africa

Chapter Seven: North America Human Immunodeficiency Diseases (HIV) market – Analysis and Revenue Forecast, 2015-2025
7.1. North America Human Immunodeficiency Diseases (HIV) market – By End-user, 2015-2025
7.1.1. HIV rapid immunoassay test
7.1.2. HIV rapid molecular diagnostic test
7.2. North America Human Immunodeficiency Diseases (HIV) market – By End-user, 2015-2025
7.2.1. Hospital
7.2.2. Clinics
7.2.3. Diagnostic Centers
7.3. North America Human Immunodeficiency Diseases (HIV) market – By Country, 2015-2025
7.3.1. U.S.
7.3.2. Canada
7.3.3. Mexico

Chapter Eight: Europe Human Immunodeficiency Diseases (HIV) market – Analysis and Revenue Forecast, 2015-2025
8.1. Europe Human Immunodeficiency Diseases (HIV) market – By End-user, 2015-2025
8.1.1. HIV rapid immunoassay test
8.1.2. HIV rapid molecular diagnostic test
8.2. Europe Human Immunodeficiency Diseases (HIV) market – By End-user, 2015-2025
8.2.1. Hospital
8.2.2. Clinics
8.2.3. Diagnostic Centers
8.3. Europe Human Immunodeficiency Diseases (HIV) market – By Country, 2015-2025
8.3.1. Germany
8.3.2. France
8.3.3. UK
8.3.4. Spain
8.3.5. Italy
8.3.6. Rest of Europe

Chapter Nine: Asia-Pacific Human Immunodeficiency Diseases (HIV) market – Analysis and Revenue Forecast, 2015-2025
9.1. Asia Pacific Human Immunodeficiency Diseases (HIV) market – By End-user, 2015-2025
9.1.1. HIV rapid immunoassay test
9.1.2. HIV rapid molecular diagnostic test
9.2. Asia Pacific Human Immunodeficiency Diseases (HIV) market – By End-user, 2015-2025
9.2.1. Hospital
9.2.2. Clinics
9.2.3. Diagnostic Centers
9.3. Asia-Pacific Human Immunodeficiency Diseases (HIV) market – By Country, 2015-2025
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. South Korea
9.3.5. Rest of Asia-Pacific

Chapter Ten: Latin America Human Immunodeficiency Diseases (HIV) market – Analysis and Revenue Forecast, 2015-2025
10.1. Latin America Human Immunodeficiency Diseases (HIV) market – By End-user, 2015-2025
10.1.1. HIV rapid immunoassay test
10.1.2. HIV rapid molecular diagnostic test
10.2. Latin America Human Immunodeficiency Diseases (HIV) market – By End-user, 2015-2025
10.2.1. Hospital
10.2.2. Clinics
10.2.3. Diagnostic Centers
10.3. Latin America Human Immunodeficiency Diseases (HIV) market – By Country, 2015-2025
10.3.1. Brazil
10.3.2. Rest of Latin America

Chapter Eleven: Middle East & Africa Human Immunodeficiency Diseases (HIV) market – Analysis and Revenue Forecast, 2015-2025
11.1. MEA Human Immunodeficiency Diseases (HIV) market – By End-user, 2015-2025
11.1.1. HIV rapid immunoassay test
11.1.2. HIV rapid molecular diagnostic test
11.2. MEA Human Immunodeficiency Diseases (HIV) market – By End-user, 2015-2025
11.2.1. Hospital
11.2.2. Clinics
11.2.3. Diagnostic Centers
11.3. Middle East & Africa Human Immunodeficiency Diseases (HIV) market – By Country, 2015-2025
11.3.1. UAE
11.3.2. Saudi Arabia
11.3.3. Turkey
11.3.4. Rest of Middle East & Africa

Chapter Twelve: Competitive Analysis
12.1.1. Competition Dashboard
12.1.2. Company Profiles
12.1.2.1. Air Liquide
12.1.2.1.1. Company Details
12.1.2.1.2. Product Portfolio
12.1.2.1.3. Financial Overview
12.1.2.1.4. Main Business Overview
12.1.2.1.5. News
12.1.2.2. Medtronic plc
12.1.2.3. Masimo Corporation
12.1.2.4. Abbott Laboratories
12.1.2.5. Bio-Rad Laboratories Inc.
12.1.2.6. Danaher Corp.
12.1.2.7. F. Hoffmann-La Roche Ltd.
12.1.2.8. QIAGEN Group

Chapter Thirteen: Appendix

Chapter Fourteen: Research Conclusions